BioXcel Therapeutics, Inc.
0 products tracked · names used in filings: BioXcel Therapeutics, Inc.
Upcoming milestones
IGALMI: PDUFA target action date (acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting)
BioXcel Therapeutics, Inc. (BTAI); dexmedetomidine; sNDA; status: set; "In the quarter ended on March 31, the FDA accepted the Company’s supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia and assigned a PDUFA target action date of November 14, 2026."; filed 2026-05-15 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.